2025 UK Pharma Services M&A and Private Equity Review

Executive Summary

Private equity investment activity and M&A in UK pharma services during 2025 was selective rather than broad-based. The year was shaped by heightened uncertainty in global pharmaceutical spending, driven by a combination of policy risk, pricing pressure and uneven demand across the sector.

Over the last 18–24 months, pharma services businesses have experienced volatile trading conditions, reflecting their close correlation to pharmaceutical R&D and commercial budgets. Decision-making by large pharma companies has slowed at times, project pipelines have become less predictable, and discretionary spend has often been delayed or re-phased rather than consistently committed.

This volatility has been amplified by external factors. In the UK, debate and revisions around the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) have reduced pricing visibility for branded medicines, feeding through to more cautious commercial planning by pharmaceutical companies. Internationally, renewed trade and tariff uncertainty, particularly linked to US political developments, has added further noise to global supply chain planning and pricing strategy.

Against this backdrop, a small number of private equity platform investments completed in 2025 across market access, clinical trial delivery, medical communications and pre-clinical services. While limited in number, these transactions provide a useful lens into where investors continue to underwrite long-term demand within pharma services, even as short-term conditions remain uneven.

Market Backdrop: Volatility, Policy and Pharma Spend

A period of heightened uncertainty

The operating environment for pharma services businesses in 2024 and 2025 has been shaped by heightened uncertainty rather than structural decline. While underlying demand for pharmaceutical innovation remains intact, the way in which spend is approved and deployed has become more constrained.

In the UK, uncertainty around the VPAG has reduced pricing visibility for branded medicines. Although VPAG does not apply directly to service providers, it has influenced pharmaceutical companies’ confidence in future UK revenues, leading to more cautious commercial and R&D budgeting.

At the same time, renewed global trade and tariff uncertainty has added further noise to planning for multinational pharma companies, contributing to tighter controls on external spend and longer internal decision-making processes.

Direct exposure to pharma budgets

Pharma services businesses are directly exposed to pharmaceutical company budgets, particularly those operating in market access, HEOR, clinical trial delivery, medical communications and pre-clinical research. As a result, changes in pharma spending patterns feed through quickly to service providers.

Over the last 18–24 months this has resulted in less predictable and lumpier revenue pipelines, delayed project initiation and expansion, and greater scrutiny of third-party spend. Importantly, this has tended to defer demand rather than remove it altogether, with projects often re-phased or re-scoped rather than cancelled.

Interpreting 2025 investment activity

This backdrop is critical when interpreting private equity investment activity in 2025. The platform investments that did complete were focused on businesses providing specialist, mission-critical services that sit close to regulatory approval, trial execution, product launch and adoption. Rather than signalling a broad market recovery, these transactions point to continued investor willingness to back platforms aligned to long-term structural demand, despite ongoing short-term volatility.

Key Investment & M&A Themes in UK Pharma Services

Advisory platforms remained investable where expertise directly influences high-stakes outcomes

Private equity continued to back advisory-led businesses where specialist capabilities inform regulatory approval, pricing, reimbursement and launch decisions. These platforms are characterised by structured, repeatable methodologies, such as HTA strategy, health economic modelling, payer research and policy engagement, rather than generalised consulting capacity.

Clinical trial delivery networks were valued for execution certainty and speed

Investment activity in Site Management Organisations reflected demand for predictable trial delivery, reliable patient recruitment and consistent quality at scale. While footprint expansion remains important, the underlying investment rationale centres on reducing execution risk for sponsors and CROs through proven delivery capability, including hybrid and decentralised trial models.

Platform strategies focused on expanding service breadth through adjacent capabilities

Where platforms articulated growth beyond their core offering, this was typically framed around adjacent services that follow the client through the development and commercial lifecycle. Examples include extending from evidence generation into access and policy support, or from access strategy into medical communications and stakeholder engagement, with the aim of increasing share of wallet and client stickiness rather than pursuing unrelated diversification.

Buy-and-build remained a central component of platform investment strategies

Most 2025 platform investments referenced organic growth alongside the potential for bolt-on acquisitions. The emphasis was on building broader, more integrated service offerings over time, with internationalisation frequently cited as a longer-term driver of bolt-on activity.

Market access offerings continued to evolve beyond technical HTA execution

Market access has evolved from a focus on HTA submissions and reimbursement decisions to a broader capability that integrates HEOR and real-world evidence with policy engagement, procurement mechanics and system navigation. This reflects the reality that positive cost-effectiveness alone is no longer sufficient to drive uptake; adoption increasingly depends on how evidence aligns with policy priorities, funding routes and provider incentives.

Notable 2025 Private Equity Investments in UK Pharma Services

Initiate Consultancy

Investor: Queen’s Park Equity

Sub-sector: Market Access

Description: Provides global market access, HEOR, pricing and reimbursement strategy services to life sciences clients, helping to prepare HTA submissions and value communication for product launches

Panthera BioPartners

Investor: LDC

Sub-sector: SMO

Description: Operates a network of clinical trial sites in the UK delivering site management, patient recruitment and study execution services for commercial clinical research

FutureMeds

Investor: Phoenix Equity Partners

Sub-sector: SMO

Description: Runs a network of UK clinical trial sites delivering site management, recruitment and study conduct services for commercial trials

Ashley Medical Communications

Investor: Hypha Partners

Subsector: Medical Communications

Description: A medical communications agency delivering scientific content, medical education and stakeholder engagement services for life sciences clients

FibroFind

Investor: Vespa Capital

Subsector: CRO

Description: A pre-clinical contract research organisation specialising in translational and ex vivo research services, supporting drug discovery and early-stage development programmes

Newmarket Strategy

Investor: Baird Capital

Subsector: Market Access

Description: A life sciences consultancy offering market access, pricing, HEOR and commercial strategy support to global pharmaceutical and biotech clients.

Notable 2025 UK Bolt-on Deals